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Importance of remission and residual somatic
symptoms in health-related quality of life among
outpatients with major depressive disorder: a
cross-sectional study
Jong-Min Woo1,2, Hong Jin Jeon3,4, Eunsun Noh5,6, Hyo-Jin Kim7, Sun Woo Lee8, Kyung Kyu Lee9,
Sung Hwan Kim10 and Jin Pyo Hong11*

Abstract
Background: Major depressive disorder (MDD) is strongly associated with an impaired quality of life (QoL), which is
itself affected by various factors. Symptom-oriented ratings poorly reflect the impact of disease on the QoL and
level of functioning of the mental health of subjects. The purpose of this study was to assess health-related QoL
(HRQoL) using preference-based measures in outpatients with MDD with regard to their remission achievement
and clinical factors affecting the HRQoL.
Methods: This was a cross-sectional observational study. We recruited 811 patients with MDD from 14 psychiatric
outpatient clinics in Korea. They were divided into three groups as follows: a new visit group (n = 287), a remitted
group (n = 235), and a non-remitted group (n = 289). The 17-item Hamilton Depression Rating Scale was used to
assign patients to the remitted or non-remitted group. The general HRQoL was assessed with the EuroQol 5D
(EQ-5D), using both the EQ-5D index score and the EuroQol Visual Analog Scale (EQ-VAS). The disease-specific
HRQoL was assessed with the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF).
Results: The non-remitted group showed a significant impairment of HRQoL in view of the subscales of EQ-5D index
scores, EQ-VAS, and Q-LES-Q-SF. The EQ-5D index score in the remitted group was 0.77 ? 0.10, while it was 0.57 ? 0.23
in the non-remitted group and 0.58 ? 0.24 in the new visit group (p < 0.0001). The EQ-VAS scores for the remitted and
non-remitted groups were 72.5 ? 16.6 and 50.9 ? 20.3, respectively (p < 0.0001). Likewise, patients with remission had
the Q-LES-Q-SF total score of 46.5 ? 8.8, whereas tho se with non-remission reported 36.7 ? 7.7 (p < 0.0001). The
symptom severity measured by the Depression and Somatic Symptoms Scale was significantly correlated with the
HRQoL. Furthermore, patients with severe somatic symptoms showed a significantly lower EQ-5D index score
(0.54 ? 0.24) than those with mild/moderate somatic symptoms (0.75 ? 0.12; p = 0.002).
Conclusion: Non-remitted MDD patients, especially those with more severe somatic symptoms, show a distinct
impairment of HRQoL and more clinical symptoms, suggesting the importance of achieving remission in the
treatment of MDD.
Keywords: Major depressive disorder, Quality of life, EQ-5D, Q-LES-Q-SF
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Introduction
Major depressive disorder (MDD) is strongly associated
with an impaired quality of life (QoL) and several studies
have investigated the factors affecting this relationship
[1-3].
Health related QoL (HRQoL) covers a wide range of
dimensions including psychological status, functional abilities, subjective well-being, social interactions, role performance and physical health [4]. Due to this nature of
HRQoL, assessment of HRQoL has received considerable
research attention and provided potential for a more comprehensive evaluation of treatment outcomes.
However, symptom-oriented ratings poorly reflect the
impact of mental health on QoL and level of functioning. Thus, QoL has been mainly assessed with patientreported outcome (PRO) instruments. Recently, the
importance of PRO measures in clinical trials for new
drug, biologic agents and devices was underscored by the
release of the US Food and Drug Administration's draft
guidance for industry [5,6].
Recently, results of the Factors Influencing Depression
Endpoints Research (FINDER) study of the European
Union demonstrated that antidepressant treatment was
associated with an improved HRQoL and that clinical factors, including the presence of somatic and painful symptoms, were negatively associated with HRQoL [1,7,8].
Depressed patients who fail to obtain full remission, which
is defined as almost full recovery of depression symptoms
to the level of a person without depression, show a higher
risk of being depressed again and continue to experience
functional impairment [9]. These results suggest that
achieving remission and severity of certain residual symptoms can be more important for improving QoL.
Previous studies suggested an impaired HRQoL in patients with depression and an improved HRQoL in treated
patients; however, the relationship between HRQoL, particularly measured using PRO and remission status is less
well understood. In our current study, we quantified both
generic and disease-specific measures of QoL and then
compared them among three subgroups (new visit, remitted, and non-remitted groups). In addition, we examined
the effect of HRQoL on suicidal thoughts and suicide attempts. We hypothesized that the non-remitted group
would show more severe impairment in QoL than the
new visit group and remitted group and, moreover, that
the severity of somatic and pain symptoms would be
closely associated with both generic and disease-specific
QoL measures.
Methods
Subjects

The data of Korean patients with MDD were derived from
the Korean Burden of Illness Study. This study was a noninterventional, multicenter-based, naturalistic observational,
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cross-sectional, and outpatient-based study of patients with
MDD. All patients were enrolled from 14 regional psychiatric outpatient clinics in Korea. The study was conducted
between December 2011 and September 2012. All study
procedures were approved by the Institutional Review
Board of Asan Medical Center and other sites. Written
informed consent was obtained from all study patients
before study initiation.
Inclusion and exclusion criteria

Patients 18 years or older and meeting the DSM-IV criteria for a single or recurrent non-psychotic MDD were
included. Each consecutive patient was evaluated according to the inclusion and exclusion criteria and was then
allocated to one of three groups: (1) a new visit group, (2)
a remitted group (17-item Hamilton Depression Rating
Scale [HAM-D-17] <8), or (3) a non-remitted group
(HAM-D-17 ≥ 8). Each hospital was allowed to consecutively allocate approximately eight patients to each group.
Groups 2 and 3 included patients who had received MDD
treatment for less than 6 months in order to exclude any
bias possibility in calculating the lost productivity costs
due to decreased social occupational function related to
other emotional problems.
Exclusion criteria included history of bipolar disorder,
schizophrenia, schizoaffective disorder, psychosis, anorexia
or bulimia nervosa, obsessive-compulsive disorder, or a
serious general medical condition.
Measurement of depressive symptoms

The 17-item HAM-D was used to measure the severity of
depressive symptoms at each visit [10]. The HAM-D-17 is
a clinician-administered depression assessment scale, evaluating mood and vegetative symptoms [10]. Each item was
rated with a score of 0-4 (where the scores are equivalent
to absent, doubtful/trivial, mild, moderate and severe) or
0? 2 (absent, doubtful/mild, and obvious, distinct/severe)
[10]. By summing the score of each item, the total scores
for HAM-D-17 can range from 0 to 54. In general, a total
HAM-D-17 score of 7 or less is accepted as an indicator of
remission [11]. It has been reported an internal consistency
of 0.83 [12], inter-rater reliability of 0.97 [13], and testretest reliability of 0.81 [14], showing adequate reliability.
Measurement of somatic symptoms

The Depression and Somatic Symptoms Scale (DSSS) was
applied to measure somatic symptoms in MDD patients
[15]. The DSSS is a 22-item self-administered rating scale
containing three subscales: a Depression Subscale (DS), a
Pain Subscale (PS), and a Somatic Subscale (SS). The DS
has 12 items, including three vegetative symptoms and fatigue, whereas the SS has 10 items, including five pain
items composed of the 5-item PS. Each item was rated
with a score of 0? 3: 0 (not at all), 1 (mild), 2 (moderate),
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or 3 (severe). Thus, the range of summed scores was 0? 66.
The scale shows a good validity and reliability, with higher
scores indicating stronger symptoms. The Korean Version
of DSSS has a Cronbach's alpha of 0.90 and shows a relatively high test-retest reliability (r = 0.83, p < 0.01) [16,17].
Measures of QoL

In order to assess HRQoL, we used generic instruments,
including the European Quality of Life-5 Dimensions
(EQ-5D; containing an index score and visual analog scale
[VAS]), and disease- or condition-specific QoL measures,
including the Quality of Life Enjoyment and Satisfaction
Questionnaire (Q-LES-Q).
EuroQol (EQ-5D and EQ-VAS)

EQ-5D is a standardized preference-based measure of
health status developed by the EuroQol Group that is
applicable to mental health conditions such as mild to
moderate depression and anxiety [18-20]. The EQ-5D
was developed to provide a simple, generic measure of
health for clinical and economic appraisals [20]. It provides a simple descriptive profile and a single index
value for health status that can be used in the clinical
and economic evaluation of health care as well as in
population health surveys. The EQ-5D is designed for
self-completion by respondents and essentially consists
of two pages. The EQ-5D descriptive system comprises
the following five dimensions (with three levels) and the
EQ visual analog scale (EQ-VAS). The EQ-5D consists
of five dimensions (mobility, self-care, usual activities,
pain/discomfort, anxiety/depression), each with three
levels of severity in health utility (no problems/some or
moderate problems/extreme problems) recording an individual? s ratings of EQ-5D health states. The Korean
version of the EQ-5D was developed and validated by
Kim et al. in 2005 [21]. The EQ-5D index score was calculated based on the weights elicited from a large national survey of the Korean population [22].
The Q-LES-Q

The Q-LES-Q is a self-report instrument designed to
measure satisfaction and enjoyment in various domains
of functioning (e.g., physical health, work, and household
duties) [23]. It can be applied to depressed individuals
[24]. Many studies have used the Q-LES-Q to measure
life satisfaction and enjoyment in patients with depression during pre- and post-treatment phases [23,25,26].
The Q-LES-Q Short Form (Q-LES-Q-SF) used in this
study consists of 16 items, of which the first 14 assess
discrete domains such as social relationships, living or
housing situation, and physical health. Item 15 concerns
the respondents? satisfaction with medication they are taking, if applicable. Item 16 is a global rating in which respondents are asked to rate their ? overall life satisfaction
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and contentment.? Each item is scored on a 5-point Likert
scale that indicates the degree of enjoyment or satisfaction
achieved during the past week (1 = very poor, 5 = very good).
Higher scores indicate better function. Items 1 through 14
of the Q-LES-Q-SF can be summed to obtain a total score,
with higher scores indicating greater life enjoyment and satisfaction. For the present analyses, we used the total score
generated by the sum of the first 14 items. This scale has a
Cronbach? s alpha of 0.90 and a test-retest reliability of 0.74
[23]. The construct validity of the Q-LES-Q is supported by
moderately negative correlations with the Clinical Global
Impressions? Severity of Illness scale (CGI-S) (r = ? 0.62 for
the summary scale) and the 17-item HAM-D, compared in
a depressed population [23]. To compare with other instruments of HRQoL we also obtained the Q-LES-Q index score
by converting the Q-LES-Q total score to a percentage.
Measures of suicidal thoughts and suicide attempts

We assessed suicide attempts and suicidal thoughts
during the past month before study inclusion using the
Korean version of the Mini-International Neuropsychiatric Interview (MINI) suicidality module [27]. The MINI
suicidality module is composed of six questions including
wish for death, wish for self-harm, suicidal thoughts, suicide plans, suicide attempts in the past month, and lifetime suicide attempts. We included the Mini-C2 (suicide
attempts in the past month) and Mini-C3 (suicidal
thoughts) in the analysis to examine the association
between HRQoL and suicidal thoughts/suicide attempts.
Statistical analysis

Descriptive statistics (mean, standard deviation) were
obtained for continuous data in each MDD patient
group. ANOVA (or Kruskal-Wallis test) was performed
to compare the patient groups. Tukey? s multiple comparison method was used for post-hoc group comparisons after the significance for ANOVA was determined.
The QoL was compared between the MDD patient
groups using ANCOVA, controlling for the depression
symptom score as covariate. The association between
the QoL and depression symptoms score was evaluated
by stepwise regression using the full set of variables of
the DSSS adjusted by age and sex. Additionally, the association between suicidal thoughts/suicide attempts and
HRQoL using logistic regression analysis was adjusted
by age and DSSS score. Frequency and percentage were
obtained for categorical data and the chi-square test was
applied to the categorical data. All analyses were performed using SAS? version 9.2 (SAS Institute, Cary, NC).

Results
Baseline characteristic of the study subjects

A total of 811 patients with MDD were included in this
study, 235 in the remitted group, 289 in the non-remitted
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group, and 287 in the new visit group. The demographics
and clinical characteristics of study subjects are presented
in Table 1. Approximately 70% of the patients were women
in each group and the mean age ranged from 44.4 to 47.6
years across the groups. There were 62.3% unemployed
subjects in the non-remitted group while the remitted
group showed an unemployment rate of 57.4%. In addition,
patients in the non-remitted group demonstrated a slightly
higher number of depressive episodes than the patients in
the remitted group (mean ? standard deviation [SD], 1.3 ?
2.2 vs. 1.7 ? 2.6) and a slightly longer duration of MDD
(7.3 ? 16.6 vs. 8.1 ? 20.5 months).
Disease severity of the subjects

Table 2 shows the symptom severity measured by 17item HAM-D scores and DSSS. Patients who achieved
remission showed a HAM-D score of 4.5 ? 2.1, which is
significantly lower than the scores of the non-remitted
group (16.6 ? 5.8) and the new visit group (17.8 ? 7.0)
(p < 0.0001). Similarly, the total scores of depressive and
somatic symptoms were significantly lower in the remitted group than in the non-remitted and new visit group.
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The depressive symptom scores in the remitted group
were 5.9 ? 5.3, whereas they were 16.8 ? 7.2 in the nonremitted group and 17.4 ? 7.2 in the new visit group
(p < 0.0001). In addition, the total score of somatic symptoms including pain was 4.0 ? 3.9 in the remitted group,
10.6 ? 6.2 in the non-remitted group, and 10.9 ? 5.8 in the
new visitors (p < 0.0001).
HRQoL

The HRQoL measured by the EQ-5D index and EQVAS and the disease-specific QoL measured by the QLES-Q-SF are described in Table 3. The EQ-5D index
score was 0.77 ? 0.10 in the remitted group and 0.57 ?
0.23 in the non-remitted group (p < 0.0001). Pain/discomfort and anxiety/depression were the two strongest
influencers of patients' HRQoL among each dimension
of EQ-5D. Approximately 65% of patients in remission
reported no problems with pain/discomfort, whereas
more than 66% of patients in the non-remitted group
reported some/severe problems with pain/discomfort.
Similar to the pain/discomfort domain, approximately
61% of the remitted group reported no problems with

Table 1 Demographics of the study subjects in the new visit, remitted, and non-remitted MDD groups
New MDD (N = 287)

Remitted MDD (N = 235)

Non-remitted MDD (N = 289)

p-value

Male

87 (30.3)

60 (25.5)

84 (29.1)

NS

Female

200 (69.7)

Testa

Sex, n (%)

Age (years)

44.4 ? 13.6

175 (74.5)
47.6 ? 11.8

205 (70.9)
44.8 ? 13.3

b

a=c<b

0.0111

b

a=c<b

b

a = b, b = c, a < c

0.0111

Marital status, n (%)
Single

63 (22.0)

36 (15.3)

62 (21.5)

Married

184 (64.1)

165 (70.2)

182 (63.0)

Bereaved

11 (3.8)

12 (5.1)

21 (7.3)

Divorced

24 (8.4)

15 (6.4)

18 (6.2)

Separated

4 (1.4)

7 (3.0)

6 (2.1)

Elementary school

40 (13.9)

32 (13.6)

46 (15.9)

Middle school

51 (17.8)

31 (13.2)

38 (13.1)

High school

107 (37.3)

105 (44.7)

121 (41.9)

University

81 (28.2)

56 (23.8)

72 (24.9)

Graduate school

7 (2.4)

11 (4.7)

12 (4.2)

Employed

128 (44.6)

100 (42.6)

109 (37.7)

Unemployed

159 (55.4)

NS

Education, n (%)
NS

Job status, n (%)

Onset of MDD (years)

41.6 ? 14.2

135 (57.4)
44.7 ? 12.6

NS

180 (62.3)
41.3 ? 14.2

Number of depressive episodes

1.1 ? 2.0

1.3 ? 2.2

1.7 ? 2.6

0.0131

Duration of depression (months)

6.3 ? 13.7

7.3 ? 16.6

8.1 ? 20.4

NS

MDD = major depressive disorder; NS = not significant.
a
Tukey? s post-hoc test.
b
Difference among MDD groups (ANOVA).
Note: Data are represented as mean ? standard deviation or number of patients (%).
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Table 2 Severity of depressive and somatic symptoms
New MDD (N = 287)
HAM-D scores

17.8 ? 7.0
c

Remitted MDD (N = 235)
4.5 ? 2.1

Unremitted MDD (N = 289)
16.6 ? 5.8

p-value

Testa

<0.0001

b

b<c<a
b<c<a

Bech scores

8.1 ? 3.5

2.0 ? 1.6

7.5 ? 2.9

<0.0001

b

Maier-Philipp scoresd

8.2 ? 3.7

1.8 ? 1.5

7.4 ? 3.2

<0.0001

b

b<c<a

b

b<c=a

e

Gibbons scores
Suicidality scores

10.7 ? 4.6

2.5 ? 1.7

10.0 ? 4.1

<0.0001

9.3 ? 8.3

6.9 ? 7.4

10.8 ? 8.8

0.0008

b

a = b, a = c, b < c

DS score

17.4 ? 7.2

5.9 ? 5.3

16.8 ? 7.2

<0.0001

b

SS score

10.9 ? 5.8

4.0 ? 3.9

10.6 ? 6.2

<0.0001

b

a=c<b
a=c<b
a=c<b

PS score

5.2 ? 3.1

2.2 ? 2.2

5.1 ? 3.4

<0.0001

b

DSSS total score

28.2 ? 11.8

9.9 ? 8.5

27.3 ? 12.3

<0.0001

b

a=c<b

MDD = major depressive disorder; HAM-D = Hamilton depression rating scale; DSSS = depression and somatic symptoms scale; DS = depression subscale of the
DSSS; SS = somatic subscale of the DSSS; PS = pain subscale of the DSSS.
a
Tukey? s post-hoc test.
b
Difference among MDD groups (ANOVA).
c
Depressed mood, feeling of guilt, work and activities, retardation, anxiety/psychic, and general somatic symptoms are included.
d
Depressed mood, feeling of guilt, work and activities, retardation, agitation, and anxiety/psychic are included.
e
Depressed mood, feeling of guilt, suicide, work and activities, anxiety/psychic, agitation, anxiety (somatic), and genital symptoms are included.
Note: Data was represented as mean ? standard deviation.

anxiety/depression, whereas 87.2% of the non-remitted
group documented some/severe problems. The HRQoL
measured by EQ-VAS was comparable to the EQ-5D
index score in each group; it was 72.5 ? 16.6 in the remitted group and 50.9 ? 20.3 in the non-remitted group
(p < 0.0001). Life satisfaction measured by Q-LES-Q-SF
was approximately 10 points higher in the remitted
group than in the non-remitted group (46.5 ? 8.8 vs.
36.7 ? 7.7; p < 0.0001). More than 95% of MDD patients
were treated with antidepressant medication and 70.8%
of the remitted group were satisfied/very satisfied with
their antidepressant medication therapy. However, only
41.8% of non-remitted patients reported that they were
satisfied/very satisfied with their medication.
Relationship between depression subscales and HRQoL

The results of multiple stepwise regression analysis between the HRQoL and depression subscales are demonstrated in Table 4. When adjusted for age and sex, the
symptom severity measured by the DSSS was significantly
associated with the HRQoL. The EQ-5D index score decreased by 0.004 in the remitted group (p = 0.0340) and
0.017 in the non-remitted group (p < 0.0001) for every
unit increase in the somatic symptom score.
Table 5 presents the HRQoL by the level of somatic
symptoms in patients over 40 years of age. Depressed
adults with severe somatic symptoms (≥8) reported a
significantly lower EQ-5D index score than those with
mild/moderate somatic symptoms (<8). This is shown
through the severity of their somatic symptoms: 0.54 ?
0.24 in those with severe symptoms versus 0.75 ? 0.12 in
those with mild/moderate symptoms (p = 0.0017), if
adjusted for depression symptoms. Specifically, patients
with mild/moderate somatic symptoms showed an EQ-5D

index score of 0.72 ? 0.14 in the non-remitted group, close
to the average EQ-5D index score in the remitted group.
Regarding disease-specific HRQoL, patients with severe
somatic symptoms presented an approximately 20% lower
mean difference in the Q-LES-Q-SF index score than
those with mild/moderate somatic symptoms (0.38 ? 0.14
vs. 0.48 ? 0.13).
Association between HRQoL and suicidal thoughts/suicide
attempts

Depression severity and impaired HRQoL were significantly associated with an increased risk of suicidal
thoughts and suicide attempts (Table 6). Non-remitted
patients showed a significantly higher risk of having
suicidal thoughts during the past month than those in
remission (odds ratio [OR] 2.55; 95% confidence interval [CI], 1.50? 4.33; p = 0.0006). Similarly, non-remitted
patients showed a significantly higher risk of having made
a suicide attempt during the past month than those in remission (OR 2.14; 95% CI, 1.08? 4.25; p = 0.0289). Furthermore, a one-unit improvement in the EQ-5D index score
had a 70% odds reduction of suicidal thoughts (OR 0.3;
95% CI 0.12? 0.75; p = 0.0104) and a 79% odds reduction
of suicide attempts (OR 0.21; 95% CI 0.08? 0.57;
p = 0.0023) in depressed patients.

Discussion
Overall results

Here, we examined the HRQoL by the remission status of
depressed patients in Korea. In the present study, the nonremitted group showed a significant impairment in HRQoL
in view of the subscales of EQ-5D index scores and the EQVAS. Similarly, the life satisfaction measured by the Q-LESQ-SF was significantly lower in the non-remitted group than
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Table 3 HRQoL (EQ-5D, EQ-VAS, Q-LES-Q-SF)
New MDD (N = 287) Remitted MDD (N = 235) Non-remitted MDD (N = 289) p-value

Testa

EQ-5D dimensions mobility, n (%)
No problems

246 (85.7)

219 (93.2)

237 (82.0)

Some problems

35 (12.2)

16 (6.8)

49 (17.0)

Severe problems

6 (2.1)

0 (0.0)

3 (1.0)

Self-care, n (%)
No problems

268 (93.4)

228 (97.0)

267 (92.4)

Some problems

19 (6.6)

7 (3.0)

21 (7.3)

Severe problems

0 (0.0)

0 (0.0)

1 (0.3)

Usual activity, n (%)
No problems

155 (54.0)

201 (85.5)

143 (49.5)

Some problems

119 (41.5)

33 (14.0)

130 (45.0)

Severe problems

13 (4.5)

1 (0.4)

16 (5.5)

Pain/discomfort, n (%)
No problems

98 (34.1)

153 (65.1)

96 (33.2)

Some problems

163 (56.8)

79 (33.6)

152 (52.6)

Severe problems

26 (9.1)

3 (1.3)

41 (14.2)

Anxiety/depression, n (%)
No problems

28 (9.8)

143 (60.9)

37 (12.8)

Some problems

189 (65.9)

90 (38.3)

192 (66.4)

Severe problems

70 (24.4)

2 (0.9)

EQ-5D index scorec

0.58 ? 0.24

0.77 ? 0.10

60 (20.8)
0.57 ? 0.23

<0.0001

b

a=c<b
a=c<b

EQ-VAS

50.3 ? 20.6

72.5 ? 16.6

50.9 ? 20.3

<0.0001

b

Q-LES-Q-SF total scored

35.6 ? 7.8

46.5 ? 8.8

36.7 ? 7.7

<0.0001

b

a=c<b

<0.0001

b

a=c<b

e

Q-LES-Q-SF index score

0.39 ? 0.14

0.58 ? 0.16

0.41 ? 0.14

Status of concomitant medication, n (%)
Yes

96 (33.4)

226 (96.2)

280 (96.9)

No

191 (66.6)

9 (3.8)

9 (3.1)

Very dissatisfied

2 (2.1)

0 (0.0)

5 (1.8)

Dissatisfied

33 (34.4)

14 (6.2)

52 (18.6)

Fair

32 (33.3)

52 (23.0)

106 (37.9)

Satisfied

27 (28.1)

136 (60.2)

106 (37.9)

Very satisfied

2 (2.1)

24 (10.6)

11 (3.9)

42 (14.6)

1 (0.4)

27 (9.3)

Satisfaction with medication, n (%)

Overall life satisfaction and contentment, n (%)
Very poor
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Table 3 HRQoL (EQ-5D, EQ-VAS, Q-LES-Q-SF) (Continued)
Poor

141 (49.1)

25 (10.6)

120 (41.5)

Fair

87 (30.3)

97 (41.3)

111 (38.4)

Good

16 (5.6)

90 (38.3)

28 (9.7)

Very good

1 (0.3)

22 (9.4)

3 (1.0)

Overall life satisfaction and contentment

2.3 ? 0.8

3.5 ? 0.8

2.5 ? 0.8

<0.0001

b

a<c<b

HRQoL = health-related quality of life; MDD = major depressive disorder; EQ-5D = European quality of life-5 dimensions; EQ-VAS = European quality of life visual
analog scale; Q? LES-Q-SF = the quality of life enjoyment and satisfaction questionnaire short form.
a
Tukey? s post-hoc test.
b
Difference among MDD groups (ANOVA).
c
EQ-5D index score = 1(0.164 + 0.003 ? M2 + 0.274 ? M3 + 0.058 ? SC2 + 0.078 ? SC3 + 0.045 ? UA2 + 0.134 ? UA3 +0.049 ? PD2 + 0.132 ? PD3 + 0.044 ? AD2 + 0.102 ?
AD3 + 0.345 ? N3 + 0.014 ? I2sq).
Where, M2 = dummy for mobility level 2, M3 = dummy for mobility level 3, SC2 = dummy for self-care level 2, SC3 = dummy for self-care level 3, UA2 = dummy for
usual activity level 2, UA3 = dummy for usual activity level 3, PD2 = dummy for pain/discomfort level 2, PD3 = dummy for pain/discomfort level 3, AD2 = dummy
for anxiety/depression level 2, AD3 = dummy for anxiety/depression level 3, N3 = 1 if there is any level 3, otherwise N3 = 0, I2sq = the square of 1 minus the
number of level 2s.
d
Summing only the first 14 items to yield a raw total score.
Each item is calculated as 1 = very poor, 2 = poor, 3 = fair, 4 = good, 5 = very good.
e
Q-LES-Q-SF index score = (Q-LES-Q-SF total score ? 14)/56.
Note: Data are represented as mean ? standard deviation or number of patients (%).

in the remitted group. Even though patients in both groups
were treated for their current symptoms of depression, patients who did not reach the treatment goals showed a significantly worse HRQoL than those who met the goals.
This finding may suggest that remission achievement in
depression plays an important role in the improvement in
the preference-based outcomes of patients.
Impact of disease severity on HRQoL

Previous research in France assessing the HRQoL using
the EQ-5D in primary care settings reported EQ-5D
index scores of 0.85 for patients in remission, 0.72 for
non-remitted patients, and 0.58 for patients who had
not responded to the treatment at the 8-week follow-up
[28]. Moreover, the FINDER study documenting the impact of antidepressant medication treatment on patients'
HRQoL found mean EQ-5D index scores of 0.75 at the
6-month follow-up [8]. Several other studies evaluating
HRQoL in depressed patients using various instruments
also presented similar utility scores when patients
achieved remission: 0.79 measured by McSad [29], 0.70

by quality of well-being [30], and 0.74 by the standard
gamble method [31].
In our study, the generic HRQoL measured via the
EQ-5D in the remitted group was consistent with the
previous research; however, the HRQoL in the nonremitted group was lower than that of previous studies.
The EQ-5D index score in our present study was similar
to the estimated EQ-5D value of the treatment nonrespondent group in the study conducted by Sapin
et al. [28]. There is evidence suggesting that having depression impairs the HRQoL [32] and that antidepressant
medication therapy helps to improve HRQoL in depressed
patients by decreasing MDD symptoms [8,33]. In our
current study, whilst more than 95% of patients in both
the remitted and non-remitted groups were treated with
antidepressant medication, satisfaction toward their medication was lowered in the non-remitted group: one of
every five patients in the non-remitted group was dissatisfied with their medication use and only 42% expressed
satisfaction in this group. Thus, most patients in the nonremitted group may not respond to their therapy and,

Table 4 Results of stepwise multiple regression analysis: Association between depression and somatic symptoms
subscales and the quality of life
Variable

New MDD (N = 287)

Remitted MDD (N = 235)

Non-remitted MDD (N = 289)

Total (N = 811)

Coefficient

p-value

Coefficient

p-value

Coefficient

p-value

Coefficient

p-value

DS score

−0.012

<0.0001

−0.010

<0.0001

-

-

−0.008

<0.0001

SS score

−0.006

0.0173

−0.004

0.0340

−0.016

<0.0001

−0.009

<0.0001

Bech score

−0.012

0.0012

-

-

-

-

-

-

Gibbons score

-

-

-

-

−0.017

<0.0001

−0.008

<0.0001

MDD = major depressive disorder; DS = depression subscale of the depression and somatic symptoms scale (DSSS); SS = somatic subscale of the DSSS.
Stepwise regression analysis using the full set of variables of the DSSS adjusted by age and sex:
Model 1: QoL (EQ-5D index score|New) = a + b1(DS score) + b2(SS score) + b3(Bech) + b4(Age) + b5(Sex).
Model 2: QoL (EQ-5D index score|Remitted) = a + b1(DS score) + b2(SS score) + b3(Age) + b4(Sex).
Model 3: QoL (EQ-5D index score|Non-remitted) = a + b1(SS score) + b2(Gibbons) + b3(Age) + b4(Sex).
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Table 5 Quality of life by somatic symptom severity
Variable

Overalla
SS ≥ 8
(n = 277)

Remitted MDD
SS < 8
(n = 279)

EQ-5D index score

0.54 ? 0.24

EQ-VAS

49.32 ? 20.57 69.03 ? 17.56 0.0003*

Q? LES-Q-SF index score 0.38 ? 0.14

0.75 ? 0.12

p-valueb SS ≥ 8
(n = 28)

0.55 ? 0.15

0.0017*

0.0008*

0.65 ? 0.19

SS < 8
(n = 155)
0.79 ? 0.07

Non-remitted MDD
p-valueb SS ≥ 8
(n = 118)
0.0139*

0.52 ? 0.24

SS < 8
(n = 67)

0.72 ? 0.14

0.0015*

61.29 ? 15.69 75.50 ? 16.18 0.0372*

47.79 ? 20.68 59.67 ? 16.91 0.2218

0.48 ? 0.13

0.38 ? 0.14

0.60 ? 0.16

0.9300

0.49 ? 0.12

p-valueb

0.2973

MDD = major depressive disorder; SS = somatic subscale of the depression and somatic symptoms scale; EQ-5D = European quality of life-5 dimensions;
EQ-VAS = European quality of life visual analog scale; Q? LES-Q-SF = the quality of life enjoyment and satisfaction questionnaire short form.
a
Patients aged 40 years or older.
b
The difference between groups was derived from ANCOVA adjusted for depression symptom scores.
*
Significance level p < 0.05.

therefore, their HRQoL is comparable to the value reported for non-responders.

Impact of somatic symptoms on HRQoL

Residual somatic symptoms could be another possible explanation for the worse HRQoL in the non-remitted
group compared with those of other studies. In our subset
analyses, after controlling for depression symptom scores,
patients with severe somatic symptoms had significantly
worse HRQoL than those who had mild/moderate somatic symptoms. Even non-remitted patients with mild/
moderate somatic symptoms showed comparable EQ-5D
index scores to those in remission. This finding indicates
that residual somatic symptoms highly influence our
patient-reported outcomes.
Several investigators have reported that the presence
of somatic symptoms, including painful physical symptoms (PPS), is associated with greater depression severity
and poor HRQoL [33-35]. Fava et al. [33] examined the
effect of antidepressant medication on PPS in depressed
patients, demonstrating that improvements in the PPS
were linked to higher remission rates. Other studies
showing the association between PPS and HRQoL suggested that patients with positive PPS at the baseline
presented 10%? 15% lower HRQoL scores (EQ-VAS of
42.2? 43.0) than those with negative PPS (EQ-VAS of
52.9? 60.4) [34,35]. The presence of PPS is still
Table 6 Association between suicidal thoughts/suicide
attempts and disease severity and HRQoL
Variable

Suicidal thoughts

Suicide attempts

ORa (95% CI)

ORa (95% CI)

Remitted

Reference

Reference

Non-remitted

2.55 (1.50? 4.33)

2.14 (1.08? 4.25)

New visit

1.56 (0.90? 2.70)

1.21 (0.59? 2.47)

0.30 (0.12? 0.75)

0.21 (0.08? 0.57)

Groups by depression severity

EQ-5D index score

EQ-5D = European quality of life-5 dimensions; OR = odds ratio;
CI = confidence interval.
a
Adjusted for age and DSSS score.

associated with less improvement in HRQoL when adjusted for depression severity [1,36].
Co-existing pain in depressed patients is highly prevalent
and more likely to be underdiagnosed and undertreated
because of the presence of the depression [37]. The prevalence of co-existing PPS in depressed patients ranges from
43% to 73%, varying by country [35,38-40]. In particular,
52% of patients with depression in Asia reported having
positive PPS [35]. Despite this awareness, more than 80%
of patients suffering from PPS were not prescribed concomitant treatment for their pain management [35]. Interestingly, the health condition with the largest negative
impact on the HRQoL in the general population is pain,
followed by depression, osteoarthritis, and anxiety [32].
Due to depressive symptoms or co-existing somatic symptoms, including PPS, depressed patients may be at higher
risk of an impaired HRQoL. Therefore, physicians or other
health care providers working with depressed patients
should pay careful attention to somatic symptoms as well
as classical depressive symptoms if such patients are seeking help regarding their depression.
Comparison between preference-based and diseasespecific HRQoL

In our present study, subjects showed lower Q-LES-Q-SF
scores as disease-specific QoL measures than those of previous studies. The scores were 46.5% in the remitted
group and 36.7% in the non-remitted group, whereas previous studies reported Q-LES-Q-SF scores of 52%? 54% in
patients with depression and 74%? 79% in subjects that
had once had depression [41,42]. The discrepancy may be
related to the different levels of severity between the studies. Previous investigations assessed the disease-specific
QoL in patients with chronic major depression or dysthymia, whereas it was assessed in subjects with more severe
depression in university hospital settings in our study.
HRQoL and suicidal thoughts/suicide attempts

In general, QoL is measured on a scale from 0 (deceased)
to 1 (completely healthy), indicating that death is the
worst state that people can imagine [19]. An impaired
HRQoL is also significantly associated with both suicidal
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thoughts and suicide attempts [43]. One study using a
population-based data survey showed that people with an
EQ-5D index score less than 0.7 were 3.4 times more
likely to attempt suicide than those with an index score of
0.8? 1.0 [43]. This study also reported that people with an
EQ-5D index score less than 0.7 had a 9.1 times increased
risk of suicidal thoughts than those with a score between
0.8? 1.0. Our study found a comparable pattern of association in patients with depression. Non-remitted patients
with a worse HRQoL showed a more than 2-fold increased risk of suicidal thoughts and suicide attempts than
those in remission. Furthermore, the improvement in
EQ-5D index scores significantly reduced both suicidal
thoughts and suicide attempts in depressed patients. Our
findings indicate the importance of achieving remission in
the treatment of depressed patients, not only for the
improvement of HRQoL, but also for the prevention of
the worst outcomes, such as suicide or death.
Strengths and limitations of the study

Our study has several limitations. First, due to the nature
of a cross-sectional study, we were unable to address the
improvement in HRQoL according to the type of treatment or total duration. However, our investigation involved
multiple sites in Korea, reflecting a similar cohort to a real
world population with depression. Furthermore, by recruiting the new visit group, we attempted to show the initial
baseline characteristics of patients who visited the hospitals. Second, the depression treatment was provided based
on the health care delivery system of each site. The possible differences between sites might have affected our
HRQoL results. To minimize unintended bias, we recruited the same number of patients from each site.

Conclusions
We evaluated the HRQoL by disease severity in patients
with depression. Non-remitted MDD patients with more
severe somatic symptoms suffer from a poorer HRQoL and
have more clinical symptoms, emphasizing the importance
of achieving remission in the treatment of subjects with
MDD in order to improve their HRQoL. In addition, the
presence of somatic symptoms is significantly associated
with impairment of HRQoL, suggesting that somatic symptoms of patients should be carefully evaluated to improve
the preference-based QoL.
Abbreviations
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